With the aim of rivaling cardiovascular medicines from Amgen Inc, Sanofi and Regeneron Pharmaceuticals, Swiss drugmaker Novartis has decided to acquire The Medicines Co , the owner of the heart drug prospect inclisiran, in a deal worth $9.7 billion hoping to take advantage of this medicine. ...